In Vivo Models
Menu
Home > Services > In Vivo Solutions > Disease Models > Humanized Models
“When people talk about ‘model organisms,’ many people think that the animal has to ‘model’ the human disease condition to have any impact. We argue that this is not the case. Simply studying what the homologous gene does in the context of the model organism can provide important insights into disease pathology. Rare genetic variants can be modeled in a number of different model organisms, informing causality between a particular variant and a pathogenic phenotype and offering clinicians and their patients hope for a diagnosis, insight into the mechanisms and pathways involved in a rare disease, and ways it might be treated.” Neff, E.P. Model matchmaking. Lab Anim 50, 39–42 (2021).
Using CRISPR and other genome editing methods, InVivo Biosystems can humanize or genetically engineer Zebrafish and C. elegans into powerful animal models for better understanding genetic mutations and disease biology discovery.
There are two types of humanizing changes can be made:
Humanization with Point Mutation
Humanization with Whole Gene
Speed
++
+
Cost
$
$$
Accuracy
+
+++
Drug Screening
+
+++
Whole gene humanization is often used to model the effects of the clinical variant.
We know we are looking at conserved biology between animal and human when the human gene rescues the function of the gene-deleted KO animal. Next we put clinical variations into the humanized locus which allows us to examine any variation (rare or common) for its functional contribution to normal biology. When we observe abnormal biology in a clinical variant, the system becomes a Human Avatar to screen drugs and find therapeutics that can restore normal function.
We have found whole gene humanization can create a platform for highly translatable results in a model organism. The gene humanization method we use replaces the ortholog locus with human cDNA. The cDNA is sequence-optimized for expression in the animal.
Gene-swap humanization technique. Ortholog gene is removed from animal (KO) to determine if defective phenotype is present. Ortholog is replaced with human coding sequence to create gene-humanized animal. Variants are installed in gene-humanized locus create Patient Avatars. Humanized animals in Patient Avatar format are phenotyped for activity defects.
Point mutation humanization is a simpler, quicker and fairly effective – CRISPR techniques to replace a single amino acid with the suspect amino acid seen in the patient. The clinical variant seen in the patient is installed in the animal’s version of the gene.
Note, this only works if sequence conservation is high and even then some variants that are pathogenic may not be at conserved positions.
In this example, the human coding sequence of STXBP1 was able to restore function when inserted as whole-gene humanization of the unc-18 locus. Referenced against a set of known pathogenic and benign variants, we were able to detect pathogenicity in a set of VUS.
Diagnostic curve for VUS assessment. (a) Transgene rescue demonstration by electrophysiology. (b) Transgene rescue demonstration by movement in liquid. (c) Deep phenotyping parameters for movement on solid surface comparis benign (green), pathogenic (red) and VUS (grey). d) diagnostic curve for pathogenicity assessment of VUS where values above harmonic mean indicate possible pathogenicity in the strain.
The video below shows that the human coding sequence of STXBP1 is inserted into the native locus of a C. elegans ortholog gene. The worms version of the gene is replaced with a human coding sequence.
– Left: the gene-swapped STXBP1 sequence functions and shows a significant level of activity.
– Middle: In contrast, the knock-out shows very little activity.
– Right: for the R406H genomic variant, its activity is somewhere in between the “humanized” and “knock-out” strain.
96 point mutations in 1 gene. All 96 mutations were created in the STXBP1 gene (which is associated with epilepsy in humans) via CRISPR. The worm homolog of STXBP1, unc-18, causes uncoordination and near-complete lack of pharyngeal pumping when knocked out. The functionality is restored by replacing the worm gene with the coding sequence for human STXBP1.
Illustration of a successful precise point mutation of stxbp1a in zebrafish. stxpb1a is a highly conserved zebrafish ortholog of human STXBP1 (87% identity). Using CRISPR/Cas9 technology, we were able to precisely generate a benign patient mutation at the conserved amino acid residue (CCC>CTG, p.P94L).
We work with scientists seeking new or alternative ways to approach their research.
InVivo Biosystems is ready to help you with your COVID-19 research! We offer our genetic expertise in the engineering of humanizations, fluorescence markers, luciferase, activity reporters, and conditional expression to help you interrogate drug and vaccine activity, binding interactions, mechanism of action, and more.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.
